A Phase II Dose-Response Study of Velcade and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
05 Nov 2013 The extension trial has been discontinued due to low accrual and the departure of the lead investigator, according to the ClinicalTrials.gov record.
19 Oct 2012 Planned end date of extension trial (NCT01062230) changed from October 2012 to December 2012, according to the ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com